FOR IMMEDIATE RELEASE: Friday, 27th September, 2019

GB- NON-01608

Media Contacts: 
Olivia Finucane 
Tel: 07881 272476

Amelia James 
01992 467272

Hoddesdon, September 27th, 2019

NEW MANAGING DIRECTOR ANNOUNCED FOR MSD IN THE UK AND IRELAND

MSD (tradename of Merck & Co., Inc., Kenilworth, N.J., USA (NYSE: MRK)) announced today that David Peacock will succeed Louise Houson as Managing Director of MSD in the UK and Ireland from October 1st.

David Peacock will bring a broad range of experience and perspectives from senior roles with the company in the United States, Singapore, Vietnam, and Japan. Most recently, David was the Chief of Staff to Kenneth C. Frazier, Chairman of the board and chief executive officer, Merck & Co., Inc., Kenilworth, N.J. (known as MSD outside the U.S. and Canada). He has also held other significant roles within the company as Managing Director of Hong Kong and Macau and the Chief Financial Officer for MSD in Japan.

David said: “I am delighted to have been appointed MD of MSD in the UK and Ireland. MSD has both a rich heritage and continued focus on scientific invention of medicines and vaccines to improve the health and wellbeing of populations and patients. I am honoured to have this
leadership role and humbled to continue MSD’s legacy here. We know we can’t solve today and tomorrow’s healthcare challenges alone, and I am looking forward to working with our team to build on our existing relationships with partners so that our innovations reach as many eligible patients as possible in the UK.”

Louise Houson, who has held the post of MD for MSD in the UK and Ireland for the past three years, will be taking on a leadership role in MSD’s global vaccines organization in the U.S.

About MSD

For more than a century, MSD, a leading global biopharmaceutical company, has been inventing for life, bringing forward medicines and vaccines for many of the world’s most challenging diseases. MSD is a trade name of Merck & Co., Inc., with headquarters in Kenilworth, N.J., U.S.A. Through our prescription medicines, vaccines, biologic therapies and animal health products, we work with customers and operate in more than 140 countries to deliver innovative health solutions. We also demonstrate our commitment to increasing access to health care through far-reaching policies, programmes and partnerships. Today, MSD continues to be at the forefront of research to advance the prevention and treatment of diseases that threaten people and communities around the world - including cancer, cardio-metabolic diseases, emerging animal diseases, Alzheimer’s disease and infectious diseases including HIV and Ebola. For more information, visit www.msd-uk.com and connect with us @MSDintheUK on Twitter, Instagram, LinkedIn, YouTube and Facebook.